“Our primary focus at Milestone is preparing for potential FDA approval of CARDAMYST nasal spray for the management of PSVT,” said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. “We believe that CARDAMYST has the potential to improve how PSVT is managed and positions Milestone to deliver meaningful value to patients, providers, and payors. Complementing our efforts in PSVT, we are very encouraged by clinician interest in the etripamil Phase 3 study in AFib-RVR which we are working toward commencing in the first half of 2025.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLSS:
- MLSS Upcoming Earnings Report: What to Expect?
- Milestone Scientific expands commercial rollout of CompuFlo Epidural System
- Benchmark starts Milestone Scientific at Speculative Buy on pain potential
- Milestone Scientific initiated with a Speculative Buy at Benchmark
- Milestone announces rollout of CompuFlo Epidural System at iHeal Pain Center